Research programme: heat shock protein 90-inhibitor drug conjugates - Madrigal Pharmaceuticals

Drug Profile

Research programme: heat shock protein 90-inhibitor drug conjugates - Madrigal Pharmaceuticals

Alternative Names: HDC SN-38; HDC-docetaxel; HSP90-inhibitor drug conjugates - Madrigal Pharmaceuticals; PEN 866; STA 12 8666; STA-8666; STA-9183

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Madrigal Pharmaceuticals
  • Class Drug conjugates; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Sep 2016 Tarveda plans a phase I/IIa trial for Cancer (Late stage disease, Topoisomerase-1 sensitive)
  • 19 Sep 2016 Madrigal Pharmaceuticals and Tarveda Therapeutics agree to co-promote and co-develop HSP90 drug conjugates in USA for Cancer
  • 22 Jul 2016 Madrigal Pharmaceuticals merged with Synta Pharmaceuticals and the combined company is now called Madrigal Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top